Asia Pacific Epilepsy Drugs Market

The Asia Pacific epilepsy drugs market was valued at US$ 2,198.72 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to grow at a CAGR of 4.6% from 2022 to 2030.

Increasing Number of Elderly People Fuels the Asia Pacific Epilepsy Drugs Market

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Asia Pacific Epilepsy Drugs Market Overview

The Asia Pacific epilepsy drugs market is analysed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively. China is the most populated country in the world and the one with the most patients with neurological disorders. According to the Centers of Disease Control and Prevention, in China, the prevalence rate of active epilepsy is 0.48% to 8.5%; there are approximately 9 million people with epilepsy in Mainland China, two-thirds of whom are children. ~30% of patients with epilepsy are not capable of controlling their seizures with the AEDs that are currently available in the market; thus, this disease has significant unmet medical needs.

Moreover, the drug approvals in the country are propelling the market growth. For instance, in August 2021, Eisai Co., Ltd. obtained two additional approvals of the antiepileptic drug (AED) Fycompa, as “a monotherapy for partial-onset seizures” and “an adjunctive treatment / a monotherapy for a pediatric indication for partial onset seizures in patients with epilepsy four years of age and older” in China from the National Medical Products Administration.

Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Drugs Market Segmentation

The Asia Pacific epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Asia Pacific epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Asia Pacific epilepsy drugs market is segmented China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific epilepsy drugs market.  

Asia Pacific Epilepsy Drugs Market Strategic Insights

Asia Pacific Epilepsy Drugs Market Segmentation Analysis

Asia Pacific Epilepsy Drugs Market Report Highlights

Asia Pacific Epilepsy Drugs Report Scope

Asia Pacific Epilepsy Drugs Market Country and Regional Insights